Anaplastic Oligodendroglioma (AO) Completed Phase 2 Trials for Temozolomide (DB00853)
Also known as: Anaplastic Oligodendroglioma / Anaplastic Oligodendrogliomas / Malignant oligodendroglioma / Oligodendroglioma, anaplastic (morphologic abnormality) / Oligodendroglioma malignant
Indication | Status | Phase |
---|---|---|
DBCOND0052374 (Anaplastic Oligodendroglioma (AO)) | Completed | 2 |
clinicaltrials.gov Identifier | Title | Purpose | Drugs |
---|---|---|---|
NCT01847235 | Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II Trial | Treatment | |
NCT00362570 | Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma | Treatment |